IPO Profile: Aimmune Therapeutics Inc

Drug developer raised $160 million in its IPO in August

1 September 2015•1 min read

[data-article-body-skeleton]{display:none!important}

JavaScript is required to read this article. Please enable it in your browser and reload the page.